The advertisement promotes the NCCN Clinical Practice Guidelines for treating AML patients, specifically highlighting the importance of retesting for FLT3 mutations and providing safety information regarding the drug XOSPATA.
Creative Information
| CID: | 12b02845-e836-40b3-9e75-8b4bb86a168f |
| CRID: | 29_672665753 |
| Domain: | xospatahcp.com |
| Seat: | Xandr |
| Size: | 300x250 |
| Bid: | $0.31 |
| Timestamp: | 11/1/2025, 4:45:18 AM |
| Declared IAB Categories: |
Analysis
5 succeeded(100% complete)
| Task | Status | Last Updated | Duration | Actions |
|---|---|---|---|---|
| ad_analysis | success | 11/20/2025, 5:09:09 PM | 6.65s | |
| adomain_analysis | success | 11/20/2025, 6:26:26 PM | 4.34s | |
| adomain_capture | success | 11/20/2025, 6:26:21 PM | 0.14s | |
| ad_render | success | 11/20/2025, 5:09:02 PM | 22.52s | |
| brand_mapping | success | 11/20/2025, 4:34:37 PM | 0.10s | |
Analysis Results
Ad Format: banner
Brands: XOSPATA
| Size: | 300x250 | ||||||||||||||||||||||
| Data Transferred: | 1495.46 KB | ||||||||||||||||||||||
| Render Time: | 8.60 Seconds | ||||||||||||||||||||||
| Creative Inferred IAB Categories: |
| ||||||||||||||||||||||
| Creative Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Domain Inferred IAB Categories: |
| ||||||||||||||||||||||
| Domain Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Landing Page: | |||||||||||||||||||||||
| Total Ad Size: | 1535.66 KB | ||||||||||||||||||||||
| Requests Made: |
|
Advertiser Domain

Ad Preview
Landing Page

Creatives

